He Sudan | Molecular Biology | Best Researcher Award Published on 02/09/202503/09/2025 by Best Achievements Prof. Dr. He Sudan | Molecular Biology | Best Researcher Award Prof. Dr. He Sudan | Suzhou Institute of Systems Medicine | China Prof. Dr. Sudan He is a Professor and Deputy Director at the Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College. She earned her Ph.D. from Peking Union Medical College and trained under Prof. Xiaodong Wang. Renowned for her pioneering work on necroptosis and regulated cell death, she has published 46 SCI-indexed papers, received over 6,200 citations, holds three patents, and serves on multiple editorial boards, making her a highly influential researcher in her field. Profiles Scopus Orcid Early Academic Pursuits Dr. Sudan He began her academic journey with a strong foundation in biomedical sciences, earning her Ph.D. from Peking Union Medical College. She honed her expertise in cell biology and immunology during her postdoctoral training in the laboratory of Professor Xiaodong Wang at the National Institute of Biological Sciences, Beijing. These early academic experiences shaped her research trajectory in regulated cell death and provided her with advanced scientific training that later enabled her to establish an independent research group at Soochow University. Professional Endeavors Dr. He has held several significant academic and leadership roles throughout her career. After joining Soochow University as a faculty member, she later relocated to the Suzhou Institute of Systems Medicine, where she built a thriving research program. In recognition of her contributions, she was appointed Deputy Director of the institute in 2023. She has also engaged extensively with industry-sponsored projects and served in editorial positions for reputed journals, contributing to the advancement of scientific publishing in her field. Contributions and Research Focus Dr. He’s research focuses on molecular mechanisms of regulated cell death, particularly necroptosis. Her pioneering work identified the essential role of RIP3 (RIPK3) in necroptosis and discovered the TLR3/4–TRIF–RIP3 axis as a key pathway in cell death. She further uncovered the ICP6-RIPK3 interaction as a host defense mechanism against viral infections. Recently, her group revealed the role of the RIP1-RIP3 complex in GVHD-associated inflammation, which opened avenues for novel therapeutic strategies now being tested in clinical trials. Impact and Influence Dr. He’s work has had a profound impact on both basic and translational research in cell death biology. Her discoveries have been published in prestigious journals such as Cell, PNAS, Nature Communications, Blood, Leukemia, and the Journal of Cell Biology. Her publications have received over 6,218 citations, reflecting her influence within the global research community. She has also contributed to drug discovery projects, particularly the identification of necroptosis inhibitors, thereby bridging the gap between fundamental biology and clinical applications. Research Skills Dr. He has demonstrated exceptional research skills in dissecting molecular signaling pathways, utilizing advanced cell biology techniques, and translating findings into clinical applications. Her expertise spans genetic manipulation, cell death assays, molecular imaging, and therapeutic target validation. She is equally adept at collaborative research, having worked with international and national partners, and at leading multidisciplinary teams to achieve groundbreaking outcomes. Her ability to integrate basic science with translational goals underscores her versatility as a researcher. Awards and Honors Dr. He has been recognized as an Elsevier Highly Cited Chinese Researcher, a testament to her research excellence and influence. She has successfully secured multiple national and industry-funded projects with a combined funding of around 3 million RMB. She has also received acknowledgment through editorial board appointments for journals like Cell Death and Disease and Frontiers in Cell Death, reflecting the academic community’s trust in her expertise. Legacy and Future Contributions Dr. He’s legacy lies in her trailblazing discoveries in necroptosis research, which have shaped current understanding of regulated cell death and its role in disease pathogenesis. Moving forward, she aims to expand her research into therapeutic applications, particularly in autoimmune diseases, inflammation, and oncology. Her ongoing clinical collaborations and translational projects suggest a promising future where her discoveries will directly influence patient care and therapeutic innovations. Publications Top Notes Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery Hepatology, 2025 Authors: Sudan Dan He, et al. Citations: 1 Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia Leukemia, 2025 Authors: Sudan Dan He, et al. Citations: 2 Inhibition of lysosome-tethered Ragulator-Rag-3D complex restricts the replication of Enterovirus 71 and Coxsackie A16 Journal of Cell Biology, 2023 (Open Access) Authors: Sudan Dan He, et al. Citations: 7 Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors European Journal of Medicinal Chemistry, 2023 Authors: Sudan Dan He, et al. Citations: 4 Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model Bioorganic Chemistry, 2023 Authors: Sudan Dan He, et al. Citations: 5 Conclusion Dr. Sudan He is an accomplished researcher whose pioneering work on regulated cell death and necroptosis has significantly advanced biomedical science. With over 6,218 citations, 46 SCI publications, and recognition as an Elsevier Highly Cited Chinese Researcher, her contributions bridge fundamental discoveries and clinical applications. As a Professor and Deputy Director, she has demonstrated exceptional leadership, innovation, and collaboration. Her ongoing projects and translational research ensure she will continue to make lasting impacts on therapeutics and global health.
Prof. Dr. Sudan He is a Professor and Deputy Director at the Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College. She earned her Ph.D. from Peking Union Medical College and trained under Prof. Xiaodong Wang. Renowned for her pioneering work on necroptosis and regulated cell death, she has published 46 SCI-indexed papers, received over 6,200 citations, holds three patents, and serves on multiple editorial boards, making her a highly influential researcher in her field. Profiles Scopus Orcid Early Academic Pursuits Dr. Sudan He began her academic journey with a strong foundation in biomedical sciences, earning her Ph.D. from Peking Union Medical College. She honed her expertise in cell biology and immunology during her postdoctoral training in the laboratory of Professor Xiaodong Wang at the National Institute of Biological Sciences, Beijing. These early academic experiences shaped her research trajectory in regulated cell death and provided her with advanced scientific training that later enabled her to establish an independent research group at Soochow University. Professional Endeavors Dr. He has held several significant academic and leadership roles throughout her career. After joining Soochow University as a faculty member, she later relocated to the Suzhou Institute of Systems Medicine, where she built a thriving research program. In recognition of her contributions, she was appointed Deputy Director of the institute in 2023. She has also engaged extensively with industry-sponsored projects and served in editorial positions for reputed journals, contributing to the advancement of scientific publishing in her field. Contributions and Research Focus Dr. He’s research focuses on molecular mechanisms of regulated cell death, particularly necroptosis. Her pioneering work identified the essential role of RIP3 (RIPK3) in necroptosis and discovered the TLR3/4–TRIF–RIP3 axis as a key pathway in cell death. She further uncovered the ICP6-RIPK3 interaction as a host defense mechanism against viral infections. Recently, her group revealed the role of the RIP1-RIP3 complex in GVHD-associated inflammation, which opened avenues for novel therapeutic strategies now being tested in clinical trials. Impact and Influence Dr. He’s work has had a profound impact on both basic and translational research in cell death biology. Her discoveries have been published in prestigious journals such as Cell, PNAS, Nature Communications, Blood, Leukemia, and the Journal of Cell Biology. Her publications have received over 6,218 citations, reflecting her influence within the global research community. She has also contributed to drug discovery projects, particularly the identification of necroptosis inhibitors, thereby bridging the gap between fundamental biology and clinical applications. Research Skills Dr. He has demonstrated exceptional research skills in dissecting molecular signaling pathways, utilizing advanced cell biology techniques, and translating findings into clinical applications. Her expertise spans genetic manipulation, cell death assays, molecular imaging, and therapeutic target validation. She is equally adept at collaborative research, having worked with international and national partners, and at leading multidisciplinary teams to achieve groundbreaking outcomes. Her ability to integrate basic science with translational goals underscores her versatility as a researcher. Awards and Honors Dr. He has been recognized as an Elsevier Highly Cited Chinese Researcher, a testament to her research excellence and influence. She has successfully secured multiple national and industry-funded projects with a combined funding of around 3 million RMB. She has also received acknowledgment through editorial board appointments for journals like Cell Death and Disease and Frontiers in Cell Death, reflecting the academic community’s trust in her expertise. Legacy and Future Contributions Dr. He’s legacy lies in her trailblazing discoveries in necroptosis research, which have shaped current understanding of regulated cell death and its role in disease pathogenesis. Moving forward, she aims to expand her research into therapeutic applications, particularly in autoimmune diseases, inflammation, and oncology. Her ongoing clinical collaborations and translational projects suggest a promising future where her discoveries will directly influence patient care and therapeutic innovations. Publications Top Notes Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery Hepatology, 2025 Authors: Sudan Dan He, et al. Citations: 1 Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia Leukemia, 2025 Authors: Sudan Dan He, et al. Citations: 2 Inhibition of lysosome-tethered Ragulator-Rag-3D complex restricts the replication of Enterovirus 71 and Coxsackie A16 Journal of Cell Biology, 2023 (Open Access) Authors: Sudan Dan He, et al. Citations: 7 Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors European Journal of Medicinal Chemistry, 2023 Authors: Sudan Dan He, et al. Citations: 4 Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model Bioorganic Chemistry, 2023 Authors: Sudan Dan He, et al. Citations: 5 Conclusion Dr. Sudan He is an accomplished researcher whose pioneering work on regulated cell death and necroptosis has significantly advanced biomedical science. With over 6,218 citations, 46 SCI publications, and recognition as an Elsevier Highly Cited Chinese Researcher, her contributions bridge fundamental discoveries and clinical applications. As a Professor and Deputy Director, she has demonstrated exceptional leadership, innovation, and collaboration. Her ongoing projects and translational research ensure she will continue to make lasting impacts on therapeutics and global health.